Aurealis Therapeutics banks $10 million in an oversubscribed round

The financing round was co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with the participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. Aurealis Therapeutics will use the funds primarily to advance the lead product AUP-16, start Phase 2 clinical trial in Diabetic Foot Ulcer (DFU) and begin preparations for clinical trials in Venous Leg Ulcer and Pressure Ulcer. Proceeds will also accelerate the preclinical development of the lead candidate AUP-55 for cancers such as ovarian and peritoneal carcinomatosis.

Chronic Wounds, deadly cancers, and inflammatory conditions are multi-factorial diseases which represent massive unmet medical needs. Aurealis Therapeutics is committed to developing curative therapies based on its multitherapy bacterial vector technology platform.

Aurealis Therapeutics built a first-in-class technology platform based on food-grade lactic acid bacteria, genetically modified to synthesize multiple human therapeutic proteins, acting as millions of nanoscale drug bioreactors in the body. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers.

The company aims to create solid clinical and health economic data in Chronic Wounds (Diabetic Foot Ulcer, Venous Ulcer, Pressure Ulcer), and deadly cancers such as ovarian cancer and peritoneal carcinomatosis. This, while engaging with strategic partners to enable market entry and ensure this game-changing technology platform will benefit millions of patients worldwide.

“AUP-16 has shown highly positive results during the Phase 1 clinical study in Diabetic Foot Ulcers: 83% of the patients who received therapeutic dose achieved complete and sustainable healing of their chronic wounds within a short treatment period while experiencing a much-improved quality of life and reduced pain. We strongly believe that our novel, transformative approach will help countless patients, provide relief to the health care system and create substantial value to all stakeholders”, commented Laurent Décory, COO of Aurealis Therapeutics.

(Press release/RAN)